Prostate Cancer - Results from #1980

Tissue contamination challenges the credibility of machine learning models in real world digital pathology. January 9, 2024

27-hydroxycholesterol and DNA damage repair: implication in prostate cancer. January 9, 2024

CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3. January 9, 2024

Adverse events and costs among non-metastatic castration-resistant prostate cancer patients. January 8, 2024

Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer. January 8, 2024

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping. January 8, 2024

Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. January 8, 2024

Clinical and functional outcomes for risk-appropriate treatments for prostate cancer. January 8, 2024

Co-designing an online treatment decision aid for men with low-risk prostate cancer: Navigate. January 8, 2024

High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker. January 8, 2024

Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells - implications for systemic control. January 8, 2024

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer. January 8, 2024

Shared decision-making before prostate cancer screening decisions. January 5, 2024

Epigenetic disruption of the RARγ complex impairs its function to bookmark AR enhancer interactions required for enzalutamide sensitivity in prostate cancer. January 5, 2024

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. January 5, 2024

Timing of High-Dose Rate Brachytherapy with External Beam Radiotherapy in intermediate and high-risk localised Prostate Cancer (THEPCA): a randomised trial. January 5, 2024

Approach to Patients with High-Risk Localized Prostate Cancer: Radiation Oncology Perspective. January 5, 2024

PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression. January 5, 2024

First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer. January 4, 2024

Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer. January 4, 2024

Page 100 of 1457